Effects of lung and airway epithelial maturation cocktail on the structure of lung bud organoids
Organoids from human pluripotent stem cells are becoming suitable models for studies of organ development, drug screening, regenerative medicine, and disease modeling. Three-dimensional minilungs in Matrigel culture have recently been generated from human embryonic stem cells. These particular organoids, named lung bud organoids, showed branching airway and early alveolar structures resembling those present in lungs from the second trimester of human gestation. We show here that the treatment of such organoids with a lung and airway epithelial maturation cocktail containing dexamethasone drives lung bud organoids to the formation of paddle-racquet like structures. This strategy may help to increase the versatility of lung organoids and to generate structures more advanced than the original branching texture.
KeywordsHuman embryonic stem cells Lung bud organoid Dexamethasone Lung epithelial maturation medium
Anterior foregut endoderm
Alveolar type II cell
Bone morphogenetic protein
Bovine serum albumin
Fetal bovine serum
Fibroblast growth factor
Human basic fibroblast growth factor
Human embryonic stem cell
Keratinocyte growth factor
Lung bud organoid
Mouse embryonic fibroblast
Paddle-racquet lung organoid
Quantitative real-time polymerase chain reaction
The respiratory system originates from buds arising from the anterior foregut endoderm (AFE) through well-defined stages of differentiation named the embryonic, pseudoglandular, canalicular, saccular, and alveolar stages. The generation of lung organoids should emulate this natural sequence of differentiation as far as possible. A number of authors have reported the generation of human lung organoids [1, 2, 3]. Dye et al. have shown the generation of small structures expressing markers of lung and airway cells, but neither branching morphogenesis nor proximodistal specification was observed [2, 3]. Snoeck’s group, however, recently described the generation of three-dimensional structures from human embryonic stem cells (hESCs) that were spatially organized in a similar way to developing lung buds in vivo; they called these lung bud organoids (LBOs). Briefly, their strategy was the following: AFE was generated from definitive endoderm (DE) in a two-dimensional sequential development as previously described [4, 5]. After that, adherent structures (during ventralization of AFE between days 6 and 8) were expanded in suspension as clumps of cells in the presence of bone morphogenetic protein (BMP) 4, fibroblast growth factor (FGF) 10, keratinocyte growth factor (KGF), the GSK3β antagonist CHIR99201, and retinoic acid (ventralization/branching medium). These LBOs structures were grown until day 25 and were then plated in Matrigel. After this, LBOs progressively underwent extensive outward branching reminiscent of saccules formed during the saccular stage of lung development and showed early signs of alveologenesis . LBOs in Matrigel contained alveolar functional type II (ATII) epithelial cells with abundant lamellar bodies.
Materials and methods
Maintenance of hESCs
AND-1, a human embryonic stem cell line, was obtained from the “Biobanco de células madre de Granada” (ISCIII, Spain) at passages 27–40. Mouse embryonic fibroblasts (MEFs) were obtained at 13.5 days postcoitum from C57BL/6 mice as described previously . This line was karyotyped and verified for mycoplasma contamination. MEFs were mitotically inactivated by overnight treatment with 2 μg/mL mitomycin C (cat. no. M4287; Sigma-Aldrich) and plated at a density of approximately 16,000 cells/cm2. AND-1 cells were cultured on MEFs under standard conditions (http://stembook.org)). The maintenance medium was composed of knockout Dulbecco’s modified Eagle’s medium (KO-DMEM; cat. no. 10829–018 Gibco; Life Technologies), 20% KO serum replacement (cat. no. 10828–010 Gibco; Life Technologies), 0.1 mM β-mercaptoethanol (cat. no. 21985–023 Gibco; Life Technologies), 2 mM Glutamax (cat. no. 35050–061, Gibco; Life Technologies), nonessential amino acids (cat. no. 11140–050 Gibco; Life Technologies), and primocin (cat. no. 12I05-MM, InvivoGen). The medium was filtered using a 0.22-μm pore filter system (cat. no. 431097, Corning), and 10 ng/mL recombinant human basic fibroblast growth factor (hbFGF; cat. no. PHG6015, Invitrogen) and 10 μM Y-27632 (cat. no. 1254, Tocris R&D Systems) were added before use. Medium was changed daily and cells were passaged either by enzymatic (the collagenase IV method) (collagenase IV; cat. no. 11140–050, Gibco; Life Technologies) or mechanical procedures (http://stembook.org). Cells were maintained in an undifferentiated state in a 5% CO2/air environment. The differentiation process was carried out under normoxic conditions unless otherwise indicated.
Primitive streak formation and induction of DE
Induction of endoderm was carried out as previously described . Briefly, primitive streak formation and endoderm induction were performed in serum-free differentiation (SFD) medium. SFD medium was composed of a mix of IMDM:F12 (3:1) media (cat. nos. B12-722F and 10–080 CVR, Corning), supplemented with N2 (cat. no. 17502–048, Gibco; Life Technologies), B27 (cat. no. 17504–044, Gibco; Life Technologies), 2 mM Glutamax (cat. no. 35050–061 Gibco; Life Technologies), 1% penicillin-streptomycin (DE17-602E, Lonza), and 0.05% bovine serum albumin (BSA; cat. no. A7906, Sigma-Aldrich). The medium was filtered using a 0.22-μm pore filter system (cat. no. 431097, Corning), and 50 μg/mL ascorbic acid (cat. no. A4554, Sigma-Aldrich) and 0.04 μL/mL monothioglycerol (stock >97%, cat. no. M6145, Sigma-Aldrich) were added before use. MEFs were depleted by passaging AND-1 onto Matrigel-coated (cat. no. 354230, Life Technologies) plates. Embryoid bodies (EBs) were formed in low-attachment six-well plates (cat. no. 3471, Corning) and maintained in SFD medium in a 5% CO2/5% O2/95% N2 environment (Galaxy 48R incubator; New Brunswick). For primitive streak formation, 10 μM Y-27632, 10 ng/mL Wnt3a (cat. no. 5036-WN, R&D Systems) and 3 ng/mL human BMP4 (cat. no. 314-BP, R&D Systems) was used. EBs were collected, resuspended carefully in endoderm induction medium containing 10 μM Y-27632, 0.5 ng/mL human BMP4, 2.5 ng/mL hbFGF, and 100 ng/mL human activin (cat. no. 338-AC, R&D Systems). Cells were fed after 36–48 h depending on cell density by removing half the old medium and adding half fresh medium.
Induction of AFE
AFE was induced as previously described . Briefly, EBs were dissociated into single cells with trypsin. Dissociated cells were transferred to a conical tube containing stop medium to neutralize the trypsin. Cells were centrifuged for 5 min at 850 rpm, washed carefully twice with SFD medium and counted. For AFE induction, 25,000–30,000 cells/cm2 were plated on fibronectin-coated (F0895, Sigma-Aldrich) 12-well tissue culture plates in AFE induction medium 1 (SFD medium supplemented with 10 mM SB-431542 (cat. no. 1614, Tocris) and 100 ng/mL of NOGGIN (cat. no. 6057, R&D Systems)). After 24 h of incubation, the medium was aspirated and AFE induction medium 2 (SFD medium supplemented with 1 μM IWP2 (cat. no. 3533, Tocris) and 10 μM of SB-431542) was added to the cultures. This process was carried out under normoxic conditions.
Formation of lung bud organoids
After AFE formation, cells were briefly trypsinized into small 3–10 cell clumps and the reaction was halted with stop medium (IMDM medium (BE12-722F) supplemented with 50% fetal bovine serum (FBS; F7524, Sigma-Aldrich), 2 mM Glutamax, 1% penicillin-streptomycin). Cells were then centrifuged for 5 min at 850 rpm and washed carefully twice with an excess of SFD medium. The clumps were plated onto low-attachment six-well plates (cat. no. 3471, Corning) in branching medium (SFD medium containing 3 μM CHIR99021, 10 ng/mL FGF10, 10 ng/mL KGF, 10 ng/mL BMP4, 50 nM all-trans retinoic acid). These three-dimensional clumps (nascent lung bud organoids) were incubated and fed every other day for approximately 20–25 days. After that, these nascent organoids were embedded into a Matrigel sandwich assembled on MW12 inserts (or transwells). Briefly, 100 μL Matrigel was loaded on the transwell insert and allowed to gel. Then nascent organoids were picked up with a wide mouth plastic Pasteur pipette, divided into MW24 wells containing 50% Matrigel diluted in branching media, and immediately transferred onto the first layer of Matrigel. After solidification of this intermediate layer containing the nascent organoids, 100 μL Matrigel was added on top. Finally, each sandwich containing various organoids was incubated with 200 μL branching media inside the transwell, and 500 μL around it. Medium inside the transwell was changed every 2–3 days. Around the transwells, the medium was added on a regular basis to maintain the bottom of the insert in continuous contact with the medium. Growing branching structures were easily visualized under the microscope after 1 or 2 weeks. These lung bud organoids or three-dimensional minilungs were treated or not with the lung and alveolar epithelial maturation cocktail (SFD medium containing 3 μM CHIR99021, 10 ng/mL FGF10, 10 ng/mL KGF, 0.1 mM IBMX, 0.1 mM 8-bromo-cAMP, and 60 nM dexamethasone) at the indicated times.
Indirect immunofluorescence of lung bud organoids
Organoids were picked up from the MW12 inserts, transferred into a well of a MW12 and fixed with 4% paraformaldehyde (PFA) for 15 min at room temperature. After that, the organoids were washed three times with phosphate-buffered saline (PBS) and incubated overnight at 4 °C with 30% sucrose. The sucrose was then exchanged for a solution of 7.5% gelatin/15% sucrose and incubated for 15 min at 37 °C. Organoids were then transferred to cryomolds containing solidified 7.5% gelatin/15% sucrose and were progressively embedded in various layers of solidified 7.5% gelatin/15% sucrose. These preparations were cut into 10-μm sections in a Leica CM3050 cryostat. Organoid sections were analyzed by indirect immunofluorescence. Briefly, the sections were washed with PBS and permeabilized with PBS/1% BSA/0.25% Triton X-100 for 5 min at room temperature. After that, the sections were washed and blocked for 30 min at room temperature with blocking solution (PBS/1% BSA). The sections were incubated for 2 h with an antibody against surfactant protein B (cat. no. sc-133143, Santa Cruz Biotech). Preparations were then washed with washing solution and incubated with a secondary antibody conjugated with Alexa fluor dye (488) from Life Technologies (A-11029) for 1 h at room temperature. Nuclei were counterstained with DAPI and samples were mounted with ProLong Diamond (P36961; Life Technologies). Cell images were captured with a fluorescence microscopy (Zeiss Axio) equipped with a camera (Axiocam MRm) and AxioVision software.
The genes analyzed, and the sequences of the oligonucleotides employed in this study
Statistical significance of data was determined by the analysis of variance followed by the Newman–Keuls or Bonferroni post-hoc tests for the experiments with three experimental groups. P < 0.05 was considered significant. Significance of the analysis of variance test is indicated in the text. Statistics were calculated with GraphPad Prism 7 software. Experiments were repeated at least two times.
We thank the core facilities of the Functional Unit for Research into Chronic Diseases (UFIEC, ISCIII) for technical help.
This work was supported by grants MPY-1038/14 and MPY-1146/16 from ISCIII to AZ and SAF-2015-71140-R from MINECO to IL.
Availability of data and materials
Please contact the corresponding author for data requests.
EM-L, CP, JM, and IL performed and designed the experiments and analyzed the data. AZ performed and designed the experiments, analyzed the data, wrote the paper, and conceived the project. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The use of the hESC line AND-1 and the experimental procedures of this study were approved by the ISCIII Ethics Committee and the National Committee of Guarantees for the Use and Donation of human Cells and Tissues (ref. no. 436351 1).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1.Chen YW, Huang SX, de Carvalho A, Ho SH, Islam MN, Volpi S, Notarangelo LD, Ciancanelli M, Casanova JL, Bhattacharya J, Liang AF, Palermo LM, Porotto M, Moscona A, Snoeck HW. A three-dimensional model of human lung development and disease from pluripotent stem cells. Nat Cell Biol. 2017;19:542–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Dye BR, Dedhia PH, Miller AJ, Nagy MS, White ES, Shea LD, Spence JR. A bioengineered niche promotes in vivo engraftment and maturation of pluripotent stem cell derived human lung organoids. Elife. 2016;5:e19732.Google Scholar
- 3.Dye BR, Hill DR, Ferguson MA, Tsai YH, Nagy MS, Dyal R, Wells JM, Mayhew CN, Nattiv R, Klein OD, White ES, Deutsch GH, Spence JR. In vitro generation of human pluripotent stem cell derived lung organoids. Elife. 2015;4. https://doi.org/10.7554/eLife.05098.
- 6.Magro-Lopez E, Guijarro T, Martinez I, Martin-Vicente M, Liste I, Zambrano A. A two-dimensional human minilung system (model) for respiratory syncytial virus infections. Viruses. 2017;9(12):E379.Google Scholar
- 8.Longmire TA, Ikonomou L, Hawkins F, Christodoulou C, Cao Y, Jean JC, Kwok LW, Mou H, Rajagopal J, Shen SS, Dowton AA, Serra M, Weiss DJ, Green MD, Snoeck HW, Ramirez MI, Kotton DN. Efficient derivation of purified lung and thyroid progenitors from embryonic stem cells. Cell Stem Cell. 2012;10:398–411.CrossRefPubMedPubMedCentralGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.